Monday, July 25, 2016

Will it never end?

Now you can fly to the Netherlands for Ampligen!



PHILADELPHIA, July 25, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on July 22. On May 23, 2016, the Company executed an amended and restated agreement with Impatients N.V., a Netherlands-based company operating as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey. Ampligen® is the trade name in the United States for rintatolimod.
“This program will enable Chronic Fatigue Syndrome (CFS) patients, who face an unmet medical need in the EU, to access rintatolimod under early access regulations,” said Tom Equels, CEO of Hemispherx. “It will operate concurrently while we work with the FDA to determine a path toward approval in the United States. The initiation and implementation of our EAP out-reach is an important tangible step in our effort to make our experimental drug Ampligen® a commercially approved drug available to all those suffering from CFS.”

 http://globenewswire.com/news-release/2016/07/25/858585/0/en/Hemispherx-Announces-First-Shipment-of-Rintatolimod-Ampligen-to-Early-Access-Program-in-Europe.html?f=22&fvtc=9&fvtv=us

Everyone link arms and sing!

A song to celebrate everything the Centers for Disease Control has done to end the Chronic Fatigue Syndrome pandemic. 

Apocalypse Then and Now

CFS Book 1

CFS Book 2

Iatrogenocide

Stonewall Massacre

The African Swine Fever

Closing Argument

Black Party

Iron Peter

Butterfly Ghosts

Audible CFS book

You can support us by listening to these songs by Charles Ortleb on Spotify.

Patient Zero

Our new bestseller about Anthony Fauci, the Bernie Madoff of AIDS and Chronic Fatigue Syndrome.

Podcasts on Spoiify

Listen to a Brief Excerpt from the Essential Book about the HHV-6 and CFS cover-up

The HHV-6 Newsletter